Facing revenue crisis, Ascletis Pharma tries to bulk up with obesity drugs
The drug maker failed to generate any revenue in the first half of 2024 even with three major commercialized products in hand
版權(quán)聲明：本文版權(quán)歸FT中文網(wǎng)所有，未經(jīng)允許任何單位或個人不得轉(zhuǎn)載，復(fù)制或以任何其他方式使用本文全部或部分，侵權(quán)必究。